Insight, China's Pharmaceutical Industry

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026

Jumpcan Pharmaceutical (SHA: 600566) announced a cooperation agreement with Shanghai‑based Thederma, securing exclusive commercialization rights in...

Company

BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised

Fineline Cube Feb 27, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q4 and full‑year 2025 financial results, with global...

Company Drug

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

Fineline Cube Feb 27, 2026

The U.S. Food and Drug Administration (FDA) approved zongertinib (Hernexeos), developed by Boehringer Ingelheim, in...

Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026

WuXi XDC (HKG: 2268), a leading global end‑to‑end CRDMO, announced a strategic collaboration with Earendil Labs,...

Others

MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection

Fineline Cube Feb 27, 2026

Merck & Co. (MSD, NYSE: MRK) announced that Prevymis (letermovir), its novel non‑nucleoside cytomegalovirus (CMV) inhibitor,...

Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026

SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL),...

Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026

The National Medical Products Administration (NMPA) released its 2025 Annual Medical Device Registration Report, highlighting...

Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Fineline Cube Feb 26, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced NMPA approval to initiate a Phase...

Policy / Regulatory

NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review

Fineline Cube Feb 26, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) officially opened...

Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026

Danaher Corporation announced a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI), a leading professional diagnostics...

Company

Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity

Fineline Cube Feb 26, 2026

Novartis (NYSE: NVS) announced plans to establish a new 46,000‑square‑foot radioligand therapy (RLT) manufacturing site in...

Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026

Novo Nordisk (NYSE: NVO) announced a strategic partnership with Vivtex Corporation to co-develop next‑generation oral biologic...

Company Drug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Fineline Cube Feb 26, 2026

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...

Company Drug

Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic

Fineline Cube Feb 26, 2026

Kexing Biopharma (SHA: 688136) announced that China’s National Medical Products Administration (NMPA) has cleared GB19 Injection...

Company Drug

Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances

Fineline Cube Feb 26, 2026

Lepu Biopharma Co., Ltd (HKG: 2157) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026

GlaxoSmithKline (GSK, NYSE: GSK) announced a definitive agreement to acquire 35Pharma Inc., a Canada‑based clinical‑stage biopharmaceutical...

Company Drug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Fineline Cube Feb 25, 2026

AstraZeneca (AZ, NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved the...

Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Fineline Cube Feb 25, 2026

Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced completion of a Phase II clinical trial for...

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026

Astellas Pharma Inc. (TYO: 4503) and Vir Biotechnology, Inc. (NASDAQ: VIR) announced a global strategic collaboration to...

Insight, China's Pharmaceutical Industry

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic

Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

You Missed

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension